OXI Stock Chart & Stats
€4.77
€0.00(0.00%)
At close: 4:00 PM EDT
€4.77
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€119.25 - €140.25
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€11.25M
Enterprise Value€13.96
Total Cash (Recent Filing)€4.96M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.00
Next Earnings
Nov 11, 2026EPS Estimate
-2.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-104.00
Shares Outstanding1,804,380
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.60Price Target Upside-45.50% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-7.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA-cleared Clinical ExpansionFDA IND clearance expands GTB-5550’s clinical development opportunity into multiple myeloma and validates progress toward human testing. This broadens the potential addressable use of the company’s lead program and creates an additional path for future clinical value creation.
Active Immuno-oncology PipelineAn actively enrolling Phase 1 pipeline provides multiple shots on goal within the company’s engineered immune-cell engager strategy. Progress across GTB-5550 and GTB-3650 can diversify development outcomes and support continued advancement of the broader TriKE platform.
No Debt BurdenZero reported debt limits interest expense and refinancing pressure, preserving more flexibility for a clinical-stage company to direct available capital toward research and trials. This is a durable balance-sheet advantage even though the company remains dependent on external financing.
Bears Say
Pre-revenue Operating ModelThe absence of revenue and continued deep operating losses show that GT Biopharma has not yet established a commercial earnings base. Until its programs generate sales, financial performance will remain tied to clinical progress, regulatory outcomes, and access to additional capital.
Persistent Cash BurnSizable negative operating and free cash flow indicates that the business consumes substantial cash to sustain operations and development. The re-acceleration in burn increases reliance on future financing and can constrain the pace or scope of clinical investment if capital access weakens.
Dilutive Financing StructureThe Series M financing improves access to capital but creates a substantial capital-structure overhang. Convertible preferred shares, warrants, additional greenshoe capacity, and full-ratchet protection can increase future common-share issuance and reduce existing holders’ economic participation.
GT Biopharma News
OXI FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was €119.25 and its highest was €140.25 in the past 12 months.
What is GT Biopharma’s market cap?
GT Biopharma’s market cap is €11.25M.
When is GT Biopharma’s upcoming earnings report date?
GT Biopharma’s upcoming earnings report date is Nov 11, 2026 which is in 52 days.
How were GT Biopharma’s earnings last quarter?
GT Biopharma released its earnings results on Aug 14, 2026. The company reported -€2.612 earnings per share for the quarter, missing the consensus estimate of -€1.741 by -€0.871.
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Overvalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate is -2.18.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 1,804,380 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
GT Biopharma reported an EPS of -€2.612 in its last earnings report, missing expectations of -€1.741. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in DE:OXI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GT Biopharma
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
OXI Stock 12 Month Forecast
Average Price Target
€2.60
▼(-45.50% Downside)
Technical Analysis
Theriva Biologics
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Azitra Inc
―